Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib study of S-222611 in patients with advanced EGFR- and/or HER2-expressing solid tumours

Next Previous
X
Search
Trial Profile

Phase Ib study of S-222611 in patients with advanced EGFR- and/or HER2-expressing solid tumours

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Sep 2018

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Epertinib (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Gastric cancer; Gastrointestinal cancer; Head and neck cancer; HER2 positive breast cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Renal cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 06 Sep 2018 Results of the extended phase Ib study (n=76) published in the European Journal of Cancer
    • 12 Dec 2015 Results (n=76) presented at the 38th Annual San Antonio Breast Cancer Symposium.
    • 29 Oct 2015 Status changed from active, no longer recruiting to completed as results of both escalation and expansion phase are published.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top